Specialized cell & gene therapy clinical development

 

Cell and gene therapies (CAGT) represent a groundbreaking force in medicine and research. These cell-based and novel gene therapies have the potential to cure a disease. It is this potential of eliminating disease that makes them so revolutionary. For the researchers and developers of these innovative therapies, continuous pursuit to improve the quality of human lives remains at the core of every clinical development decision made toward advancing CAGT therapeutic options.

Developing successful cell and gene therapy clinical trials is a complex process due to many operational challenges and regulatory scrutiny. As biotech companies embark on clinical trial planning and execution, it is critical to find a CRO delivery partner to help anticipate and navigate these operational complexities that arise when designing and running clinical trials for cell and gene therapies.

Our dedicated Cell & Gene Therapy team brings complementary strategic guidance plus delivery excellence – resulting in increased value for our biotech customers and a better experience for patients.
Erin Finot, Vice President, Immuno-Oncology & CAGT

CAGT Study Management Team

Answering the call for innovation to address specific challenges of cell and gene therapy drug development, we have formed a multidisciplinary Cell and Gene Therapy Study Management team. This comprehensive unit is designed for CAGT-focused biotech partners, integrating the IQVIA Biotech clinical program strategy and delivery with the IQVIA Cell and Gene Therapy Center of Excellence. Together, these groups form your CAGT Study Management team, dedicated to an end-to-end, seamless experience for biotech customers.

Aligned CAGT Strategy and Delivery

We believe that having our CAGT operational delivery as a streamlined process is at the heart of your program’s success. Because of this, we design your delivery strategy with the following core principles:

  • Seamless CAGT solutions applied throughout the study process
  • Dedicated CAGT-expert cross-functional delivery teams
  • Medical expertise across all therapeutic areas
  • Clinical trial design, delivery and logistics support
  • Optimized communication to efficiently achieve trial milestones
  • Integrate lessons learned and experiences into innovation and value for patients
Contact Us
Site Selection
Cell and gene therapy trials require integration and coordination across numerous disciplines, such as a leukapheresis center, cell therapy laboratory, investigational pharmacy, in-patient treatment facility, and outpatient clinics. Our team works with sites to confirm they have the requisite equipment and processes, appropriate handling knowledge, and trained staff and expertise to support cell and gene therapy studies and patients. Additionally, investigator relationships, networks, and thought leader support are paramount to concluding a comprehensive site identification strategy and running a high-quality study.
Regulatory
Global regulatory planning and an understanding of regional landscapes are critical to the success of CAGT development. These trials are often evaluated by specialized committees or local standards and the reviews differ from country to country. The regulatory landscape has changed recently with the EU CTR 536/2014, and it is important for biotech companies to understand the current state and anticipate the future state, both of which may impact their CAGT development goals. Our regulatory experts help customers navigate regulatory considerations with strategic and operational guidance.
Logistics
CAGT clinical trials have tremendous logistical complexities, from the manufacturing supply chain of precious cell materials to the frequency of biospecimen collection during the clinical trial. A dedicated team member will oversee all communication, planning and logistics to minimize risk at sample handovers and ensure compliance and reconciliation of samples. Our innovative technology solutions can help ensure superior compliance and tracking, as well as risk mitigation of the logistics chain.
Experienced Teams
  • Supported 80+ full-service CAGT clinical trials for biotech sponsors in the past 10 years 
  • More than 70% of Project Managers have 3+ years of CAGT experience
  • 100% dedicated to biotech customers

Navigating Operational Complexities

The CAGT Study Management team can help sponsors navigate operational challenges specific to cell and gene therapy trials including site selection and start-up, regulatory requirements, and intense logistical demands of product distribution and biospecimen collection. We provide data-driven guidance to enhance the probability of operational success.

Drive smarter decisions with IQVIA Connected Intelligence

Our powerful approach brings together CAGT experts, data-driven insights, global site networks, and innovative technologies to help you drive smarter decisions to accelerate CAGT clinical development.

Related Solutions
Real World Solutions

Generate and disseminate the right real world evidence (RWE) to meet stakeholder needs with confidence.

Decentralized Trials

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are.

Cell & Gene Therapy COE

Access new resources for advanced therapy development, from candidate identification through market authorization.